DNA Torsional Solitons in Presence of localized Inhomogeneities

In the present paper we investigate the influence of inhomogeneities in the dynamics and stability of DNA open states, modeled as propagating solitons in the spirit of a Generalized Yakushevish Model. It is a direct consecuence of our model that there exists a critical distance between the soliton's center of mass and the inhomogeneity at which the interaction between them can change the stability of the open state.Furtherly from this results was derived a renormalized potential funtion.Comment: RevTex, 13 pages, 3 figures, final versio

N,N-Dimethoxy-N-tert-alkylamines: new synthesis methods and the crystal structure of the precursor

Under the methanolysis of N-methoxy-N-(1-pyridinium)amines salts 1a–c, nucleophilic substitution occurs at the nitrogen atom to form N,N-dimethoxyamines 2a,b; the crystal structure of precursor 1c has been studied

N,N-Dimethoxy-N-tert-alkylamines: new synthesis methods and the crystal structure of the precursor

Under the methanolysis of N-methoxy-N-(1-pyridinium)amines salts 1a–c, nucleophilic substitution occurs at the nitrogen atom to form N,N-dimethoxyamines 2a,b; the crystal structure of precursor 1c has been studied

ABOUT ORGANIZING AND CONDUCTING THE MEASURES OF PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME IN NOVOSIBIRSK REGION

Clinic-and-epidemiological characteristics of suspected «atypical pneumonia» cases detected in NovosibirskRegion, organizing of early detection of ill persons and their hospitalizing are presented. Main organizing-methodical and administrative-ordering measures directed on preventing of SARS delivery and spreading on the territory of Region are reflected.The organizational measures for preventing of «atypical pneumonia» allowed to avert its delivery and spreading in the Region, and to conduct the complex of treatment-and-diagnosis and anti-epidemic measures in suspected SARS cases

Symmetry Influence on the Rotation of Molecules in Crystals

© 2017 American Chemical Society. It was shown that rotational mobility of molecules in crystals is affected by the symmetry of their surroundings. A hypothesis was proposed for the discovered correlation. Three cases are possible for the location of the molecules with respect to the crystallographic symmetry elements: I - the location in a general position; II - the location in special positions without symmetry disordering; III - the location in special positions with symmetry disordering. According to the experimental data, the rotation barrier heights at the location of the molecules in cases I and III are lower than in case II. This fact is explained by the amplitude and p hase shifts of the rotational energy profiles of two parts of the molecule in case I and by increasing the number of minima on the rotation barrier profile at disordering the molecules by symmetry in case III. The way is proposed for lowering the rotational barrier of molecules in crystals

Non-commutative Geometry and Kinetic Theory of Open Systems

The basic mathematical assumptions for autonomous linear kinetic equations for a classical system are formulated, leading to the conclusion that if they are differential equations on its phase space $M$, they are at most of the 2nd order. For open systems interacting with a bath at canonical equilibrium they have a particular form of an equation of a generalized Fokker-Planck type. We show that it is possible to obtain them as Liouville equations of Hamiltonian dynamics on $M$ with a particular non-commutative differential structure, provided certain geometric in character, conditions are fulfilled. To this end, symplectic geometry on $M$ is developped in this context, and an outline of the required tensor analysis and differential geometry is given. Certain questions for the possible mathematical interpretation of this structure are also discussed.Comment: 22 pages, LaTe

DC-electric-field-induced and low-frequency electromodulation second-harmonic generation spectroscopy of Si(001)-SiO2_2 interfaces

The mechanism of DC-Electric-Field-Induced Second-Harmonic (EFISH) generation at weakly nonlinear buried Si(001)-SiO$_2$ interfaces is studied experimentally in planar Si(001)-SiO$_2$-Cr MOS structures by optical second-harmonic generation (SHG) spectroscopy with a tunable Ti:sapphire femtosecond laser. The spectral dependence of the EFISH contribution near the direct two-photon $E_1$ transition of silicon is extracted. A systematic phenomenological model of the EFISH phenomenon, including a detailed description of the space charge region (SCR) at the semiconductor-dielectric interface in accumulation, depletion, and inversion regimes, has been developed. The influence of surface quantization effects, interface states, charge traps in the oxide layer, doping concentration and oxide thickness on nonlocal screening of the DC-electric field and on breaking of inversion symmetry in the SCR is considered. The model describes EFISH generation in the SCR using a Green function formalism which takes into account all retardation and absorption effects of the fundamental and second harmonic (SH) waves, optical interference between field-dependent and field-independent contributions to the SH field and multiple reflection interference in the SiO$_2$ layer. Good agreement between the phenomenological model and our recent and new EFISH spectroscopic results is demonstrated. Finally, low-frequency electromodulated EFISH is demonstrated as a useful differential spectroscopic technique for studies of the Si-SiO$_2$ interface in silicon-based MOS structures.Comment: 31 pages, 14 figures, 1 table, figures are also available at http://kali.ilc.msu.su/articles/50/efish.ht

Молекулярный портрет рака желудка, ассоциированного с вирусом Эпштейна–Барр

Epstein–Barr virus (EBV) associated gastric carcinoma is a special form of gastric adenocarcinoma that arises against the background of clonal growth of EBV-infected epithelial cells of the gastric mucosa. This subtype of tumors has unique genetic and epigenetic features that determine its characteristic phenotype. Determination of the molecular features of EBV-associated gastric cancer made it possible to identify potential targets for drug therapy of this subtype of tumors. The review presents modern data on the epidemiology and pathogenesis of EBVassociated gastric cancer, describes its unique pathomorphological and molecular features. Particular attention is paid to the prognostic role of EBV infection and drug therapy potentially applicable to the treatment of EBV-positive gastric cancer.Рак желудка, ассоциированный с вирусом Эпштейна–Барр (ВЭБ), – особая форма онкологического заболевания, возникающая в результате клональной пролиферации ВЭБ-инфицированных эпителиоцитов слизистой оболочки желудка. Данный подтип опухолей имеет уникальные генетические и эпигенетические особенности, определяющие его характерный фенотип. Выявление широкого спектра молекулярных особенностей ВЭБ-ассоциированного рака желудка позволяет описать потенциальные мишени, перспективные для лекарственной терапии данного подтипа опухолей. В обзоре представлены современные данные об эпидемиологии и патогенезе ВЭБ-ассоциированного рака желудка, описаны его уникальные патоморфологические и молекулярные особенности. Особое внимание уделено прогностической роли ВЭБ-инфекции и лекарственной терапии, потенциально применимой для лечения ВЭБ-положительного рака желудка

Эффективность и безопасность индукционной химиотерапии по схеме FOLFIRINOX при погранично резектабельном и нерезектабельном раке поджелудочной железы

Objective. To evaluate efficacy and safety of FOLFIRINOX regimen as induction therapy in borderline resectable and unresectable pancreatic cancer.Materials and methods. A prospective study included patients with borderline resectable and unresectable pancreatic cancer without distant metastases. Patients received up to 6 courses of induction chemotherapy with FOLFIRINOX regimen (oxaliplatin 85 mg/m2 i. v., irinotecan 180 mg/m2 i. v., calcium folinate 400 mg/m2 i. v., 5‑fluorouracil 400 mg/m2 i. v. bolus and 2 400 mg/m2 i. v. 46‑hours infusion) repeated every 14 days. Patients underwent surgery when radiologic signs of resectability were achieved. Maintenance chemotherapy was prescribed to the patients in cases of unresectability preservation. The primary endpoint was 1‑year progression-free survival.Results of the study. The study included 32 patients. The median follow-up was 7.0 months. The one-year progression-free survival was 55.3%. The one-year overall survival of patients in this study was 83.2%. Eight patients (25%) underwent surgery after induction therapy, and in 7 of them it was possible to perform R0 resection. The main manifestations of 3–4 grade toxicity were neutropenia (46.9%), diarrhea (12.5%), and elevation of hepatic transaminases (12.5%).Conclusions. The FOLFIRINOX regimen showed high potential as induction chemotherapy in pancreatic cancer. The use of this regimen is possible only in patients with good performance status due to its high toxicity.Цель исследования. Оценить эффективность и безопасность применения режима FOLFIRINOX в качестве индукционной терапии при погранично резектабельном и нерезектабельном раке поджелудочной железы.Материалы и методы. В проспективное исследование включались пациенты с погранично резектабельным и нерезектабельным раком поджелудочной железы без отдаленных метастазов. Пациенты получали до 6 курсов индукционной химиотерапии по схеме FOLFIRINOX (оксалиплатин 85 мг/м2 в/в, иринотекан 180 мг/м2 в/в, фолинат кальция 400 мг/м2 в/в, 5‑фторурацил 400 мг/м2 в/в стр. и 2400 мг/м2 в/в 46‑час. инфузия) каждые 14 дней. При достижении рентгенологических признаков резектабельности пациентов оперировали. В случае сохранения нерезектабельности пациентам назначалась поддерживающая химиотерапия. Основной конечной точкой была одногодичная выживаемость без прогрессирования.Результаты исследования. В исследование включено 32 пациента. Медиана длительности наблюдения составила 7,0 месяцев. Одногодичная выживаемость без прогрессирования составила 55,3%. Одногодичная общая выживаемость пациентов в данном исследовании составила 83,2%. Восемь пациентов (25%) прооперировали после индукционной терапии, у 7 из них удалось выполнить R0‑резекцию. Основными проявлениями токсичности 3–4 степени были нейтропения (46,9%), диарея (12,5%), а также рост печеночных трансаминаз (12,5%).Выводы. Режим FOLFIRINOX показал высокую активность в качестве индукционной химиотерапии рака поджелудочной железы. Применение данного режима возможно только для пациентов с хорошим соматическим статусом в связи с его высокой токсичностью

Оценка токсичности и эффективности терапии комбинацией FOLFIRI и афлиберцепта при метастатическом раке толстой кишки в РФ: первые результаты многоцентрового ретроспективного исследования

oai:oai.tumors.elpub.ru:article/629Purpose. To assess the incidence and severity of adverse events; to explore clinical factors associated with grade 3–4 non-hematologic toxicity; to assess the immediate efficacy and progression-free survival during treatment with the FOLFIRI regimen in combination with aflibercept in Russia.Materials and Methods. A retrospective multicenter study has been conducted with data collected from 20 clinics in 15 regions of Russia. There was no statistical hypothesis. Progression-free survival was the main efficacy criterion. The statistical analysis was performed using IBM SPPS Statistics v. 20 software.Results. FOLFIRI and Aflibercept combination was administered to 264 patients. The mean number of treatment cycles was 6 (1 to 29). The toxicity of aflibercept was addressed by dose reduction and dosing delay in 10.1 % and 11.4 % of patients, respectively, and dose reductions and dosing delays in any of FOLIFRI components were reported in 20.1 % of participants. The objective response rate was 20.3 %. The median progression-free survival in patients receiving second-line treatment was 6 months (95 % CI: 5.3–6.6 months). Seventy-two percent of patients experienced any grade of adverse events most of which were limited to grade 1–2 (62.1 %). Non-hematologic toxicity was reported in 64 % of patients (grade 3–4 in 17.9 %). Hematologic events were detected in only 17.9 % of patients. Multifactorial analysis has shown that drug therapy for concomitant diseases (OR 1.98, 95 % CI: 1.04–3.78, p = 0.037) and the number of chemotherapy lines prior to aflibercept (ОR 1.5, 95 % CI: 1.06–2.11, p = 0.02) were independent predictors of grade 3–4 non-hematologic toxicity.Conclusions. Objective response rate, progression-free survival, and frequency of toxicity-related aflibercept discontinuations in the Russian study with patients receiving aflibercept in combination with FOLFIRI regimen as a second-line treatment has shown the results that were comparable with VELOUR study. Comorbidities requiring drug treatment and the number of prior chemotherapy lines appear to be risk factors for grade 3–4 nonhematological toxicity events. Цель исследования. Оценить частоту развития и тяжесть нежелательных явлений; изучить клинические факторы, ассоциированные с развитием негематологической токсичности 3-4 степени; оценить непосредственную эффективность выживаемость без прогрессирования при применении комбинации FOLFIRI с афлиберцептом в РФ.Материалы и методы. Проведено ретроспективное многоцентровое исследование. Собраны данные 20 клиник 15 регионов РФ. Статистическая гипотеза отсутствовала. В качестве основного критерия эффективности рассматривалась выживаемость без прогрессирования. Статистический анализ проводился с помощью программ статистического пакета SPSS (IBM SPPS Statistics v. 20).Результаты. Режим FOLFIRI афлиберцепт был назначен у 264 пациентов. Среднее число составило 6 (от 1 до 29). В связи с токсичностью доза афлиберцепта в процессе терапии была редуцирована у 10,1% пациентов, задержали очередное введение афлиберцепта — у 11,4%; отсрочка и редукция доз химиопрепаратов в режиме FOLFIRI описана у 20,1 %. Частота объективных эффектов составила 20,3%. Во второй линии терапии медиана выживаемости без прогрессирования составила 6 месяцев (95% ДИ 5,3-6,6 месяцев). Нежелательные явления любой степени зарегистрированы у 72 % пациентов и чаще были ограничены 1-2 степенью (62,1%). Негематологические осложнения развились у 64% (3-4 степень — у 17,9%). Гематологические осложнения представлены только у 17,9 % пациентов. По результатам многофакторного анализа лекарственная терапия по поводу сопутствующей патологии (ОШ 1,98, 95%ДИ 1,04-3,78, р=0,037) и число линий терапии (ОШ 1,5, 95%ДИ 1,06-2,11, р=0,02), предшествующих афлиберцепту, явились независимыми предсказывающими факторами развития нежелательных явлений негематологического профиля 3-4 степени.Выводы. Частота объективных эффектов, выживаемость без прогрессирования и частота отмены афлиберцепта в связи с токсическими реакциями при применении комбинации FOLFIRI + афлиберцепт во второй линии среди пациентов в РФ аналогична результатам исследования VELOUR. Сопутствующая патология, требующая медикаментозной коррекции, и число линий терапии предшествующих афлиберцепту, по-видимому, являются факторами риска развития негематологических явлений 3-4 степени